AstraZeneca’s antibody cocktail fails to protect against coronavirus

  • AstraZeneca’s antibody cocktail fails to protect against coronavirus

AstraZeneca’s antibody cocktail fails to protect against coronavirus

"In the overall trial population, AZD7442 reduced the risk of developing symptomatic COVID-19 by 33 per cent compared to placebo, which was not statistically significant", the company said.

Meanwhile, a study published Monday by British health authorities showed that two doses of the Pfizer-BioNTech and AstraZeneca vaccines prevent hospitalization by more than 90 percent after infection with the "Delta" COVID-19 strain that first emerged in India.

The country's vaccination campaign started on February 26 with some virus-vulnerable groups and front-line medical workers being prioritized for inoculations.

Results for a subset of participants who were not infected to begin with was more encouraging but the primary analysis rested on results from all participants.

"While this trial did not meet the primary endpoint against symptomatic illness, we are encouraged by the protection seen in the PCR negative participants following treatment with AZD7442".

The company is banking on further studies to revive the product's fortunes.

"The phenomenal pace of the UK's vaccination programme has allowed us to refine our approach to possible antibody treatments and we are investigating several, including through a network of national platform trials".

The Korea Disease Control and Prevention Agency (KDCA) announced the list of third-quarter vaccine recipients to achieve its goal of vaccinating 36 million people in the country of 51.3 million by September.

AZD7442 is produced from two long-acting monoclonal antibodies acquired from plasma of convalescent COVID-19 patients.

The AstraZeneca coronavirus vaccine is now only recommended for people over 60, after the nation's immunisation expert panel updated its advice amid concerns over a "rare but sometimes very serious" blood clotting syndrome.

The Anglo-Swedish drugmaker, which has faced a rollercoaster of challenges with the rollout of its COVID-19 vaccine, is also developing new treatments and repurposing existing drugs to fight the virus.

On March 16 this year, AstraZeneca had announced an extended agreement with the United States government to supply up to 5,00,000 additional doses of AZD7442 for $205 million, contingent on AZD7442 receiving Food and Drug Administration's emergency use authorisation in post-exposure prophylaxis.

Shares in the company were largely unchanged on the London Stock Exchange.